Print pageEmail pageRSS Feeds

News releases

The news releases listed below were believed to be accurate in all material respects at the time of original issuance. Please note that we do not intend, and assume no obligation, to update, correct, or otherwise modify any of these press releases for events that occur subsequent to the original release date. We suggest you review the more recent press releases in order to receive the most current information made available by ARIAD.

Keyword Search
 
2014 | 2013 | 2012 | 2011
DateTitle 
04/16/14ARIAD to Webcast Conference Call on First Quarter 2014 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 16, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its first quarter 2014 financial results on Wednesday, May 7, 2014, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update. The live webcast can be accessed by visi... 
Printer Friendly Version
04/02/14ARIAD Announces Appointment of Hugh Cole, Senior Pharmaceutical-Industry Executive, as Chief Business Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 2, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Hugh M. Cole to the position of senior vice president and chief business officer. Mr. Cole will be responsible for global business and corporate development, licensing and strategic planning. He will report to ARIAD’s chairman and chief executive officer, Harvey J. Berger, M.D. Hugh Cole, senior vice president and... 
Printer Friendly Version
03/24/14ARIAD Announces Initiation of Pivotal Phase 2 ALTA Trial of AP26113 in Patients with Non-Small Cell Lung Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 24, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initiation of a pivotal global Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who were previously treated with crizotinib. The ALTA (ALK in Lung Cancer Trial of AP26113) trial is designed to determine the safety and efficacy of AP26113 in refractory NSCLC patients who ... 
Printer Friendly Version
02/25/14ARIAD Reports 2013 Financial Results and Outlines Key Objectives for 2014
Conference Call Scheduled Today at 8:30 a.m. ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 25, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. “I am extremely pleased with the commercial and R&D progress we made in 2013, especially ending the year with Iclusig commercially available to ... 
Printer Friendly Version
02/24/14ARIAD to Present at the Cowen and Company 34th Annual Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 24, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Cowen and Company 34th Annual Health Care Conference being held in Boston. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s business on Tuesday, March 4, at 10:40 a.m. (ET). The ARIAD presentation will be webcast live and can be accessed by vi... 
Printer Friendly Version
02/21/14ARIAD Expands Its Board of Directors with Appointment of Alexander J. Denner, Ph.D. of Sarissa Capital Management
Additional Independent Director to be Appointed to ARIAD Board CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 21, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the appointment of Alexander J. Denner, Ph.D. to a two-year term on the Company’s Board of Directors, effective immediately. With the addition of Dr. Denner, who serves as the chief investment officer and founding partner of Sarissa Capital Management LP, the Board now compr... 
Printer Friendly Version
02/19/14ARIAD to Present at the RBC Capital Markets Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 19, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the RBC Capital Markets Healthcare Conference being held in New York City. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s business on Wednesday, February 26, at 3:05 p.m. (ET). The ARIAD presentation at the RBC Capital Markets Healthcare Conference ... 
Printer Friendly Version
02/10/14ARIAD to Host Conference Call and Webcast Discussion of Fourth Quarter and Year-End 2013 Financial Results on February 25, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 10, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its fourth quarter and year-end 2013 financial results on Tuesday, February 25, 2014, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update. The live webcas... 
Printer Friendly Version
02/05/14ARIAD to Present at the Leerink Swann Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 5, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Leerink Swann Global Healthcare Conference being held in New York City. Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer, will provide an overview of the Company’s business on Wednesday, February 12, at 11:05 a.m. (ET). The ARIAD presentation at the Leerink Sw... 
Printer Friendly Version
01/28/14ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Australia
CAMBRIDGE, Mass. & MELBOURNE, Australia--(BUSINESS WIRE)--Jan. 28, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Specialised Therapeutics Australia Pty Ltd (STA), a specialty pharmaceutical company, today announced that ARIAD has granted STA exclusive rights to commercialize Iclusig® (ponatinib) in Australia in patients with Philadelphia-positive (Ph+) leukemias. Under the terms of the agreement, STA will be responsible for obt... 
Printer Friendly Version
01/17/14ARIAD Announces the Commercial Availability of Iclusig (Ponatinib) for Patients with Refractory Philadelphia-Positive Leukemias in the U.S.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 17, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the commercial availability of Iclusig® (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and... 
Printer Friendly Version
01/14/14ARIAD and Medinol Announce Initiation of Two Registration Trials of the NIRsupreme™ Ridaforolimus-Eluting Stent for Use in Coronary Artery Disease
CAMBRIDGE, Mass. & TEL AVIV, Israel--(BUSINESS WIRE)--Jan. 14, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Medinol, Ltd. today announced the initiation of two registration trials of Medinol’s NIRsupremeTM Ridaforolimus-Eluting Coronary Stent System incorporating ARIAD’s mTOR inhibitor, ridaforolimus. The two NIRsupreme clinical trials are randomized, single-blind, global studies taking place in the United States, Europe, Israel and C... 
Printer Friendly Version
01/13/14Biologics Selected by ARIAD to Be the Exclusive Specialty Pharmacy Provider for Iclusig (ponatinib)
January 13, 2014 07:30 AM Eastern Standard Time CARY, N.C.--(BUSINESS WIRE)--Biologics, Inc., an integrated oncology services company, is pleased to announce that it has been selected by ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) to be the sole specialty pharmacy provider of Iclusig® (ponatinib) and manager of its Patient Access and Support Services (ARIAD PASSTM) program. Iclusig is a treatment for adult patients with refractory chronic myeloid leukemia or Philadelphia-chromosome positive (... 
Printer Friendly Version
01/02/14ARIAD to Present at the 32nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 2, 2014-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the 32nd Annual J.P. Morgan Healthcare Conference being held in San Francisco. Harvey J. Berger, M.D., chairman and chief executive officer, will provide an overview of the Company’s business on Tuesday, January 14 at 3:00 p.m. (PT). The ARIAD presentation at the J.P. Morgan Healthcare Conference will be ... 
Printer Friendly Version
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue